Literature DB >> 32529273

Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody.

Kevin P Labadie1, Jonathan G Sham2.   

Abstract

Mesh：

Year:  2020        PMID： 32529273     DOI： 10.1245/s10434-020-08702-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.

Authors:  Zheng Wang; Zhenggang Ren; Yi Chen; Jie Hu; Guohuan Yang; Lei Yu; Xinrong Yang; Ao Huang; Xin Zhang; Shaolai Zhou; Huichuan Sun; Yanhong Wang; Ningling Ge; Xiaoyu Xu; Zhaoyou Tang; Wanyee Lau; Jia Fan; Jiping Wang; Jian Zhou
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

2.  High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma.

Authors:  Shintaro Takaki; Takayuki Fukuhara; Nami Mori; Keiji Tsuji
Journal:  Mol Clin Oncol       Date:  2019-11-18

3.  Serum cholinesterase is an excellent biomarker of liver cirrhosis.

Authors:  Jeyamani Ramachandran; K G Sajith; Sophiya Priya; Amit K Dutta; K A Balasubramanian
Journal:  Trop Gastroenterol       Date:  2014 Jan-Mar

4.  Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Authors:  Jing-Hang Jiang; Zhe Guo; Hao-Feng Lu; Xiao-Bo Wang; Hao-Jie Yang; Fu-Quan Yang; Si-Yang Bao; Jian-Hong Zhong; Le-Qun Li; Ri-Rong Yang; Bang-De Xiang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

5.  Long-term prognostic factors of patients with hepatocellular carcinoma who survive over 10 years after hepatectomy.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Hirofumi Kamachi; Akinobu Taketomi
Journal:  J Surg Oncol       Date:  2020-03-20       Impact factor: 3.454

6.  Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis.

Authors:  Yifan Tong; Zheyong Li; Yuelong Liang; Hong Yu; Xiao Liang; Hui Liu; Xiujun Cai
Journal:  Oncotarget       Date:  2017-04-18

7.  Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.

Authors:  Jia-Zhou Ye; Jun-Ze Chen; Zi-Hui Li; Tao Bai; Jie Chen; Shao-Liang Zhu; Le-Qun Li; Fei-Xiang Wu
Journal:  World J Gastroenterol       Date:  2017-11-07       Impact factor: 5.742
  7 in total
  1 in total

1.  The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.

Authors:  Linghong Guo; Honghong Ren; Lutong Pu; Xingyu Zhu; Yin Liu; Xuelei Ma
Journal:  Cancer Manag Res       Date:  2020-08-13       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.